reported enhanced proliferation and anti-tumor activity in a lower-affinity CD19 CAR compared with that in clinical high-affinity CAR (CD19) T cells, indicating that the increased immunoreceptor affinity may adversely affect T cell responses. Here, CD19 is linked to neoplasm.